<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576912</url>
  </required_header>
  <id_info>
    <org_study_id>1501015242</org_study_id>
    <nct_id>NCT02576912</nct_id>
  </id_info>
  <brief_title>Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone</brief_title>
  <acronym>THC-Preg</acronym>
  <official_title>Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to examine the effect of pregnenolone (PREG) on the
      acute psychosis-like and cognitive effects of Delta-9-tetrahydrocannabinol (THC). This will
      be tested by pretreating healthy individuals with PREG and then assessing their responses to
      THC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale for Schizophrenia (PANSS)</measure>
    <time_frame>Baseline, +110, +180, and +240 minutes after start of THC Infusion</time_frame>
    <description>Positive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered Dissociative Symptoms Scale (CADSS)</measure>
    <time_frame>Baseline; +15, +110, +180, and +240 minutes after start of THC infusion</time_frame>
    <description>Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-reported items and 9 clinician-rated items. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline; +15, +110, +180, and +240 minutes after start of THC infusion</time_frame>
    <description>Feeling states associated with cannabis intoxication will be measured using a self-reported visual analog scale of feeling states associated with cannabis effects (ex: &quot;high,&quot; &quot;calm,&quot; &quot;anxious&quot;). Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line. These data will be captured to validate that the experiment is relevant to cannabis effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotomimetic States Inventory (PSI)</measure>
    <time_frame>Baseline; +110, +180, and +240 minutes after start of THC infusion</time_frame>
    <description>The PSI is a measure of drug induced psychotomimetic states. This self-reported scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Test Battery</measure>
    <time_frame>25 minutes after start of THC infusion</time_frame>
    <description>Several computer tasks will be administered in order to evaluate the effects of cannabis on verbal learning and memory, visual recognition, spatial working memory, and working memory. The battery consists of five computer tasks that lasts no longer than 20 minutes in total.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Active Delta-9-THC and Placebo Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Delta-9-THC and Active Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Delta-9-THC and Active Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Delta-9-THC and Placebo Pregnenolone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Delta-9-THC</intervention_name>
    <description>Active Delta-9-THC (0.036 mg/kg) given intravenously.</description>
    <arm_group_label>Active Delta-9-THC and Placebo Pregnenolone</arm_group_label>
    <arm_group_label>Active Delta-9-THC and Active Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Pregnenolone</intervention_name>
    <description>A dose given sublingually.</description>
    <arm_group_label>Active Delta-9-THC and Active Pregnenolone</arm_group_label>
    <arm_group_label>Placebo Delta-9-THC and Active Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo dose given sublingually.</description>
    <arm_group_label>Active Delta-9-THC and Placebo Pregnenolone</arm_group_label>
    <arm_group_label>Placebo Delta-9-THC and Placebo Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dose given intravenously.</description>
    <arm_group_label>Placebo Delta-9-THC and Active Pregnenolone</arm_group_label>
    <arm_group_label>Placebo Delta-9-THC and Placebo Pregnenolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exposed to cannabis at least once in lifetime.

        Exclusion Criteria:

          -  Cannabis naive

          -  Individuals with a documented reaction/allergy to Pregnenolone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Sanders, BA</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4495</phone_ext>
    <email>ashley.sanders@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Luddy, BS</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4549</phone_ext>
    <email>christina.luddy@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Sanders, BA</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4495</phone_ext>
      <email>ashley.sanders@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Luddy, BS</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4549</phone_ext>
      <email>christina.luddy@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deepak C D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>Marijuana</keyword>
  <keyword>THC</keyword>
  <keyword>Pregnenolone</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>PREG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

